Loading clinical trials...
Loading clinical trials...
Primary objective: \- To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD). Secondary objective: \- To determine plasma concentrat...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sanofi
NCT06615804 · Major Depressive Disorders
NCT06239740 · Major Depressive Disorders, Cognitive Dysfunction
NCT02972398 · Major Depressive Disorders
NCT02681822 · Alzheimer Disease, Schizophrenia, and more
NCT02590185 · Major Depressive Disorders
Sanofi-Aventis Administrative Office
Buenos Aires
Sanofi-Aventis Administrative Office
Santiago
Sanofi-Aventis Administrative Office
Athens
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions